HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC/DoJ clearance procedures

This article was originally published in The Rose Sheet

Executive Summary

Any future agreement on merger clearance procedures would have to satisfy Senate Commerce Committee Chairman Fritz Hollings' (D-S.C.) concerns about concurrent jurisdiction, particularly for media mergers. FTC, DoJ notified Hollings, who also chairs Senate Appropriations/Commerce Subcommittee, May 20 that they would not follow through with March 5 agreement that divvied up jurisdiction by industry (1"The Rose Sheet" April 22, 2002, p. 8). Proposed compromise that would have given FTC jurisdiction over one-third of cable mergers was rejected by Commerce Committee staff May 17. DoJ cited "prospect of budgetary consequences" if it stood by original agreement; supplemental appropriations bills, marked up in Senate May 22, was potential vehicle for budget, salary cuts for agencies...

You may also be interested in...

Sen. Hollings Mulling Salary Freeze For FTC Chairman, Commissioners

A potential salary freeze against the Federal Trade Commission's five commissioners and senior staff, if enacted, would slow down the majority of FTC's operations indefinitely, according to the agency

UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline

UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.


New Indications For Diabetes Drugs Under The Spotlight At EMA

Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts